This dual GIP/GLP-1 receptor agonist, approved by the FDA for type 2 diabetes and chronic weight management, may cause dizziness through several mechanisms including dehydration from gastrointestinal side effects, medication interactions affecting blood pressure, hypoglycemia when combined with insulin or sulfonylureas, and orthostatic hypotension related to weight loss
During the 52-week treatment period and 4-week follow-up, the incidence rates of treatment-emergent adverse events (TEAEs) in adult patients receiving 100 mg Resmetirom (325 patients), 80 mg Resmetirom (327 patients), placebo (320 patients), and 100 mg Resmetirom in an open-label trial (171 patients) were 86.1%, 88.4%, 81.8%, and 86.5%, respectively
doi: 10.1007/s00125-015-3660-2 16 WolvertonDBlairMM
Glutathione is found in high concentrations in the follicular fluid surrounding developing eggs